ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
BMS' Opdivo+Yervoy combo fails in small cell lung cancer
November 28, 2018Bristol-Myers Squibb has revealed that its combo comprising Opdivo (nivolumab) and Yervoy (ipilimumab) failed to meet its primary endpoint as a maintenance treatment for extensive-stage -
KOL Views: How does Opdivo’s stumble shift the balance of power in SCLC?
October 17, 2018KOL Views Imfinzi Keytruda Opdivo Tecentriq AstraZeneca BMS Merck & Co. Roche EMA FDA Lung Cancer Pulmonary/Respiratory Medicine Marketing & Sales Medical Affairs -
G1 Therapeutics Unveils Positive Mid-Stage Data for Myelopreservation in SCLC Patients
March 06, 2018A mid-stage program aimed at treating myelosuppression in lung cancer patients undergoing chemotherapy is yielding positive results
Pharma Sources Insight January 2025
